Alzheimer’s disease - Articles and news items

Motor neurone disease onset delayed by AI-discovered drug

Industry news / 25 May 2017 / Niamh Marriott, Junior Editor

The study assessed the efficacy of a drug candidate proposed by BenevolentAI’s artificial Intelligence technology for Motor Neuron Disease (MND)…

Alzheimer’s experts call for changes in FDA drug approval standards

Industry news / 12 May 2017 / Niamh Marriott, Junior Editor

Leading Alzheimer’s disease researchers published an analysis urging the FDA to clarify and modernise its approach for approval of Alzheimer’s drugs…

Amarantus forms Elto Pharma for CNS Disorders and MANF Therapeutics for Ophthalmology

Industry news / 18 April 2017 / Niamh Marriott, Junior Editor

Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus’ mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer’s Aggression and Parkinson’s disease Levodopa-induced Dyskinesia (PD-LID). Concurrently, Amarantus has formed the […]

Trial uses herpes drugs to slow down Alzheimer’s disease

Industry news / 20 December 2016 / Niamh Louise Marriott, Digital Editor

The first clinical study to investigate if herpes virus drugs can have an effect on fundamental Alzheimer’s disease processes has been launched…

Alzheimer’s disease: reviewing the immediate treatment horizon

Blog, Z Homepage promo / 5 September 2016 / Stuart Goodman, Blue Latitude Health

Blue Latitude Health’s Stuart Goodman discusses the latest progress in Alzheimer’s disease research and treatment to find out why a cure remains elusive…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...